Quick Answer
Lyell Immunopharma, Inc. reported Common Stock Shares Outstanding of 21.25 million shares for the year ending 2025.
- Lyell Immunopharma, Inc. showed an increase of +44.1% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Lyell Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: 238.55 million shares | Q3 2021: 239.79 million shares | Q1 2022: 245.42 million shares | Q2 2022: 247.11 million shares | Q3 2022: 249.24 million shares | Q1 2023: 249.61 million shares | Q2 2023: 251.03 million shares | Q3 2023: 251.87 million shares | Q1 2024: 254.93 million shares | Q2 2024: 255.95 million shares | Q3 2024: 256.56 million shares | Q1 2025: 295.28 million shares | Q2 2025: 14.83 million shares | Q3 2025: 19.29 million shares.
- Over the full 6 years of available data (2020 to 2025), Lyell Immunopharma, Inc.'s Common Stock Shares Outstanding has grown by 36.5%.
- Historical annual values: Fiscal year 2025: 21.25 million shares | Fiscal year 2024: 14.74 million shares | Fiscal year 2023: 253.96 million shares | Fiscal year 2022: 249.57 million shares | Fiscal year 2021: 242.74 million shares | Fiscal year 2020: 15.57 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: